Form 4: Spero Therapeutics Director Cynthia Smith Reports Acquisition of 20,000 Shares of Common Stock

Director Cynthia Smith reports acquiring 20,000 shares of Spero Therapeutics common stock on May 29, 2024, bringing her total holdings to 55,000 shares.

Summary

• Cynthia Smith, a director of Spero Therapeutics, filed a Form 4 with the SEC.
• The form reports a transaction that occurred on May 29, 2024.
• Smith acquired 20,000 shares of Spero Therapeutics common stock.
• The acquisition was in the form of restricted stock units (RSUs) at a price of $0.00.
• Following the transaction, Smith beneficially owns 55,000 shares of common stock.
• The RSUs vest on May 29, 2025, contingent upon Smith's continued service.
• The filing was signed by Satyavrat Shukla, Attorney-in-Fact for Cynthia Smith, on May 30, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock acquisition by a director. The acquisition itself could be seen as mildly positive, but the filing is primarily informational.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service through the applicable vesting date.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by a director could be perceived positively by shareholders.

Key Dates